BioSpace News Archive

Elevation Oncology, Inc. today announced that it has expanded its ongoing Phase 1 clinical trial of EO-3021 outside the United States, dosing the first patient in Japan.

Lisata Therapeutics, Inc. today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products.

Apnimed, Inc. today announced the company will participate in the Evercore ISI 2024 Emerging Biotech Conference taking place virtually on February 28-29, 2024.

Cardiff Oncology, Inc. today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading.

Salarius Pharmaceuticals, Inc. announced that its Board of Directors is implementing a series of additional cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025.

Kane Biotech Inc. Dr. Robert Huizinga was elected as a director of the Company.

OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”) today announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced positive topline results from the Phase 2a Carpo trial evaluating TP-05, a novel, investigational oral therapeutic for the prevention of Lyme disease.